Fulcrum Therapeutics (FULC) Accumulated Depreciation (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Accumulated Depreciation data on file, last reported at $15.2 million in Q1 2026.

• On a quarterly basis, Accumulated Depreciation rose 4.21% year-over-year to $15.2 million in Q1 2026; TTM through Mar 2026 was $15.2 million, a 4.21% increase from a year earlier, with the FY2025 full-year figure at $15.6 million, up 9.75% from the prior year.
• Accumulated Depreciation for Q1 2026 stood at $15.2 million, down from $15.6 million in the prior quarter.
• Over the last five years, Accumulated Depreciation for FULC reached as high as $15.6 million in Q4 2025 and fell as low as $8.8 million in Q1 2022.
• Historically, Accumulated Depreciation has averaged $12.8 million across 5 years, with a median of $13.2 million in 2024.
• Across the five-year window, Accumulated Depreciation surged 31.19% in 2022 and advanced 4.21% in 2026, its largest moves.
• Year by year, Accumulated Depreciation stood at $10.7 million in 2022, then increased by 19.68% to $12.8 million in 2023, then climbed by 11.73% to $14.3 million in 2024, then increased by 9.75% to $15.6 million in 2025, then declined by 2.7% to $15.2 million in 2026.
• Per Business Quant data, the three most recent Accumulated Depreciation figures were $15.2 million in Q1 2026, $15.6 million in Q4 2025, and $15.3 million in Q3 2025.